The role of HE4 in ovarian cancer follow-up: A review

International Journal of Gynecological Cancer

Volumn 24, Issue 8, 2014, Pages 1359-1365

  Piovano, Elisa ^a   Attamante, Lorenza ^a   Macchi, Chiara ^a   Cavallero, Camilla ^a   Romagnolo, Cesare ^b   Maggino, Tiziano ^c   Landoni, Fabio ^d   Gadducci, Angiolo ^e   Sartori, Enrico ^f   Gion, Massimo ^g   Zola, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b G Fracastoro Hospital   (Italy)

^c Dell'Angelo Hospital   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g Department of Clinical Pathology   (Italy)

Author keywords

CA 125; Follow up; HE4; Ovarian cancer; Recurrence

Indexed keywords

CA 125 ANTIGEN; CA 72-4 ANTIGEN; HE4 PROTEIN; MATRILYSIN; MESOTHELIN; PLACENTA PROTEIN 14; PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

CANCER RECURRENCE; CYTOREDUCTIVE SURGERY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNORADIOMETRIC ASSAY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; OVARIAN NEOPLASMS; PHYSIOLOGIC MONITORING; PHYSIOLOGY; PROCEDURES;

FEMALE; HUMANS; MONITORING, PHYSIOLOGIC; OVARIAN NEOPLASMS; PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84925654957     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000218     Document Type: Review

References (20)

1. Granato T, Midulla C, Longo F, et al. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol. 2012;33:1335-1339.
2. Parkin DM, Pisani P, Ferlay J. Estimates of theworldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827-841.
3. Plotti F, Capriglione S, Terranova C, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33:2117-2123.
4. Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374-382.
5. van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104:863-870.
6. Anastasi E, Marchei GG, Viggiani V, et al. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010;31:113-119.
7. Ferraro S, Braga F, Lanzoni M, et al. Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273-281.
8. Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11:1199-1209.
9. Ledermann JA, Raja FA, Fotopoulou C, et al.; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi24-vi32.
10. Ovarian Carcinoma. Amsterdam, the Netherlands: Association of Comprehensive Cancer Centres (ACCC); 2009:53.
11. th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95:S161-S192.
12. Schummer M, Drescher C, Forrest R, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012;125:65-69.
13. Manganaro L, Michienzi S, Vinci V, et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep. 2013;30:2481-2487.
14. Braicu EI, Chekerov R, Richter R, et al. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse. Ann Surg Oncol. 2014;21:955-962.
15. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40-46.
16. Rustin G, van der Burg M, Griffin C, et al.; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomized trial. Lancet. 2010;376:1155-1163.
17. Fleming ND, Cass I, Walsh CS, et al. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;121:249-252.
18. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-9343.
19. Morris RT, Monk BJ. Ovarian cancer: relevant therapy, not timing, is paramount. Lancet. 2010;376:1120-1122.
20. Al Rawahi T, Lopes AD, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2:CD008765.